Ticagrelor Tablet
Product Images NDC 69452-509

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 69452-509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60mg-500ct (60mg 500ct)

60mg-500ct (60mg 500ct)
Label for Ticagrelor Tablets 60 mg oral tablets from Bionpharma Inc. The label includes usage instructions, storage conditions, manufacturer details (Changzhou Pharmaceutical Factory, China), and package size of 500 tablets. It displays the NDC code 69452-508-30 and a barcode.*
FDA Label Image

60mg-60ct (60mg 60ct)

60mg-60ct (60mg 60ct)
Label for Ticagrelor 60 mg tablets manufactured by Changzhou Pharmaceutical Factory and distributed by Bionpharma Inc. The label includes dosage strength, quantity of 60 tablets, storage instructions, and a barcode. The product is prescription only, oral tablets, with labeler Bionpharma Inc.*
FDA Label Image

90mg-500ct (90mg 500ct)

90mg-500ct (90mg 500ct)
Label for Ticagrelor Tablets 90 mg, oral dosage form, containing 500 tablets per container. The label includes the NDC 69452-509-30 and the manufacturer listed as Changzhou Pharmaceutical Factory, Changzhou, Jiangsu, China. Distributed by Bionpharma Inc., Princeton, NJ. Storage instructions and warning about keeping out of reach of children are also shown.*
FDA Label Image

90mg-60ct (90mg 60ct)

90mg-60ct (90mg 60ct)
Label for Ticagrelor Tablets 90 mg oral tablets, supplied in a package of 60 tablets. This prescription drug label shows the NDC 69452-509-17 and states that the tablets are manufactured by Changzhou Pharmaceutical Factory in China and distributed by Bionpharma Inc. The label includes storage instructions, a warning to keep out of reach of children, and dispensing guidance.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of Ticagrelor, showing its molecular arrangement with various functional groups and rings, including a fluorinated aromatic ring and multiple hydroxyl groups.*
FDA Label Image

Figure-01 (Figure 01)

Figure-01 (Figure 01)
A cumulative percentage line graph comparing two treatments, Ticagrelor 90 mg and Clopidogrel, over 360 days from the first study drug dose. The y-axis shows cumulative percentage, and the x-axis shows days. Ticagrelor 90 mg shows a higher cumulative percentage than Clopidogrel throughout the study period. The number of patients at risk decreases over time for both groups.*
FDA Label Image

Figure-02 (Figure 02)

Figure-02 (Figure 02)
A bar chart depicting the percentage of patients who had an event following CABG over a period of days, comparing two groups labeled T and C. The x-axis represents days, and the y-axis shows the percentage of patients. Below the bars, numerical data are provided corresponding to each group and day.*
FDA Label Image

Figure-03 (Figure 03)

Figure-03 (Figure 03)
A line graph comparing cumulative percentage (%) over months from randomization for Ticagrelor versus placebo. The x-axis represents time in months, ranging from 0 to 54, and the y-axis shows cumulative percentage from 0% to 7%. Two curves illustrate that Ticagrelor has a higher cumulative percentage of events than placebo over time. A table below the graph shows the number of patients at risk at different time points for both groups.*
FDA Label Image

Figure-04 (Figure 04)

Figure-04 (Figure 04)
A cumulative percentage plot comparing Ticagrelor 90 mg twice daily (solid line) with placebo (dashed line) over days from randomization. The vertical axis shows cumulative percentage, and the horizontal axis shows days from randomization up to 34 days. The number at risk for each group is presented below the x-axis. Ticagrelor shows a higher cumulative percentage compared to placebo.*
FDA Label Image

Figure-05 (Figure 05)

Figure-05 (Figure 05)
A line graph comparing the IPA (%) induced by 20uM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. The graph shows Ticagrelor reaching near 90% IPA quickly and maintaining it, Clopidogrel increasing more gradually to about 50%, and placebo remaining low near 10% at 8 hours.*
FDA Label Image

Figure-06 (Figure 06)

Figure-06 (Figure 06)
A line graph showing IPA (%) induced by 20 µM ADP plotted against time in days, with three data series represented by circle, triangle, and square markers. An inset graph shows IPA (%) induced by 20 µM ADP over 48 hours with the same marker styles. The y-axis depicts IPA percentage, and the x-axis shows time (days for the main graph, hours for the inset).*
FDA Label Image

Figure-07 (Figure 07)

Figure-07 (Figure 07)
A forest plot chart showing mean effect and 90% confidence interval (CI) for Ticagrelor and AR-C124910XX under various intrinsic factors including age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and mild hepatic impairment. The chart compares Cmax and AUC for these factors and states no dose adjustment is recommended across all categories.*
FDA Label Image

Figure-08 (Figure 08)

Figure-08 (Figure 08)
A chart displaying the mean effect and 90% confidence interval (CI) of various interacting drugs on the pharmacokinetics (Cmax and AUC) of Ticagrelor and AR-C124910XX. It lists interacting drugs on the left and provides recommendations on the right, including dose adjustments and cautions such as avoiding concomitant use for certain inhibitors. The horizontal axis shows change relative to reference.*
FDA Label Image

Figure-09 (Figure 09)

Figure-09 (Figure 09)
A chart showing the mean effect and 90% confidence intervals of various interacting drugs on Ticagrelor pharmacokinetics, specifically Cmax and AUC values. The chart lists drugs such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine, alongside recommendations about dose adjustments relative to Ticagrelor dosing.*
FDA Label Image

Figure-10 (Figure 10)

Figure-10 (Figure 10)
A line graph comparing cumulative percentage of events over 360 days from randomization between Ticagrelor 90 mg and Clopidogrel. The x-axis represents days from randomization, and the y-axis shows cumulative percentage. The graph includes survival analysis data with hazard ratio, p-value, and number of patients at risk over time for each treatment group.*
FDA Label Image

Figure-11 (Figure 11)

Figure-11 (Figure 11)
A forest plot chart comparing the overall treatment effect of Ticagrelor versus Clopidogrel across various patient subgroups. The plot includes hazard ratios with 95% confidence intervals for different characteristics such as geographic region, dosage of ASA, treatment approach, history of diabetes, age groups, sex, and race. The x-axis ranges from 0.25 to 4.0, indicating treatment benefit direction for Ticagrelor or Clopidogrel.*
FDA Label Image

Figure-12 (Figure 12)

Figure-12 (Figure 12)
A forest plot showing risk hazard ratios (HR) with 95% confidence intervals comparing Ticagrelor to Clopidogrel, categorized by ASA dose levels and region (US and Non-US). The plot visualizes treatment effect sizes and confidence intervals for each subgroup alongside numerical tabulated data.*
FDA Label Image

Figure-13 (Figure 13)

Figure-13 (Figure 13)
A line chart showing cumulative percentage over days from randomization comparing Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. The chart includes cumulative event percentages and number of patients at risk at various time points up to about 1300 days, with a legend indicating sample sizes and statistical values such as hazard ratios and p-values.*
FDA Label Image

Figure-14 (Figure 14)

Figure-14 (Figure 14)
A forest plot presenting hazard ratios (HR) and 95% confidence intervals (CI) comparing Ticagrelor versus placebo across various patient subgroups. The chart summarizes treatment effects for Ticagrelor 60 mg and 90 mg oral tablets, displaying HR values for overall treatment, age groups, sex, race, weight, BMI, geographic region, medical history, and other clinical characteristics.*
FDA Label Image

Figure-15 (Figure 15)

Figure-15 (Figure 15)
A line graph comparing cumulative percentage over months from randomization between Ticagrelor and placebo groups. The x-axis represents months from randomization (0 to 54), and the y-axis shows cumulative percentage from 0 to 14%. Ticagrelor is represented by a solid line, placebo by a dashed line. A table below the x-axis shows the number at risk at various time points for both groups.*
FDA Label Image

Figure-16 (Figure 16)

Figure-16 (Figure 16)
A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals for various patient characteristics between Ticagrelor and placebo groups. The chart visually represents treatment effects across subgroups including age, sex, race, body mass index, geographic region, baseline aspirin dose, HbA1c, kidney function, insulin use, history of angina, coronary artery disease, PCI, CABG, smoking status, and diabetes duration.*
FDA Label Image

Figure-17 (Figure 17)

Figure-17 (Figure 17)
A Kaplan-Meier curve chart comparing cumulative event percentages over days from randomization for Ticagrelor 90 mg twice daily versus placebo. The y-axis shows cumulative percentage, the x-axis shows days, and a table below indicates the number of subjects at risk over time for both groups. The graph depicts Ticagrelor's lower cumulative event percentage compared to placebo.*
FDA Label Image

Figure-18 (Figure 18)

Figure-18 (Figure 18)
A forest plot chart illustrating the hazard ratio (HR) and 95% confidence intervals for Ticagrelor versus placebo across various patient characteristics, including age, sex, race, weight, BMI, geographic region, diagnosis, diabetes, hypertension, prior conditions, statin treatment, and smoking status. The plot shows HR values with corresponding patient counts and percentages, comparing Ticagrelor and placebo treatment groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.